Jaguar Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Jaguar Health, Inc. on April 18, 2019. The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in San Francisco, California. The report addresses a specific corporate governance event rather than periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the departure of a senior executive:
- Event: Resignation of Chief Commercial Officer.
- Individual: Mr. Robert J. Griffing.
- Entity: Napo Pharmaceuticals, Inc., a wholly-owned subsidiary of Jaguar Health, Inc.
- Effective Date: April 18, 2019 (immediate).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies related to the resignation. No unusual items were disclosed in this report.
Key Facts for Investor Verification
- Confirm the immediate departure of Robert J. Griffing as Chief Commercial Officer of the subsidiary Napo Pharmaceuticals, Inc.
- Verify if a successor has been appointed or if the role is being backfilled.
- Review subsequent filings for any impact on the company's commercial strategy or pipeline development.